Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
+1.74%
1,094.89
+18.76
+1.74%
—1,076.131,079.891,095.291,079.89——
SIXC
Communications
SIXC
Communications
SIXC
-0.40%
604.29
-2.45
-0.40%
—606.74606.74607.90603.06——
SIXE
Energy
SIXE
Energy
SIXE
+0.06%
1,249.51
+0.69
+0.06%
—1,248.821,246.371,254.511,239.08——
SIXI
Industrials
SIXI
Industrials
SIXI
+0.92%
1,740.23
+15.87
+0.92%
—1,724.361,733.021,745.751,727.76——
SIXM
Financials
SIXM
Financials
SIXM
+0.16%
636.58
+0.99
+0.16%
—635.59635.08636.74633.31——
SIXR
Staples
SIXR
Staples
SIXR
+0.24%
845.19
+2.04
+0.24%
—843.15842.50846.70840.85——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0.37%
215.49
-0.80
-0.37%
—216.29216.29216.91215.24——
SIXT
Technology
SIXT
Technology
SIXT
+1.74%
3,320.31
+56.90
+1.74%
—3,263.413,296.253,330.113,295.42——
SIXU
Utilities
SIXU
Utilities
SIXU
+0.33%
942.34
+3.10
+0.33%
—939.24941.57944.25939.87——
SIXV
Health care
SIXV
Health care
SIXV
+0.34%
1,467.48
+4.92
+0.34%
—1,462.561,465.031,470.171,459.66——
SIXY
Discretionary
SIXY
Discretionary
SIXY
+0.79%
2,399.15
+18.75
+0.79%
—2,380.402,394.922,412.132,394.92——
Q1 2026 earnings • 5:00 PM today
See details
EXEL:NASDAQ
Exelixis Inc
$44.93
+1.81%
(+0.76) 1D
May 5, 11:02:54 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for EXEL...
Open
$44.45
High
$45.21
Low
$44.43
Mkt. cap
11.46B
Avg. vol.
2.34M
Volume
608.22K
P/E ratio
16.18
52-wk high
$49.40
52-wk low
$33.76
EPS
$2.78
Beta
0.38
Shares outstanding
254.01M
No. of employees
1K
News stories
From sources across the web
Profile
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration for medullary thyroid cancer with clinical activity in several other types of metastatic cancer. Wikipedia
About Exelixis Inc
CEOMichael M. Morrissey
Employees1.08K
FoundedNov 15, 1994
HeadquartersAlameda, California, United States
SectorBiotechnology
Websiteexelixis.com
Next call in 5:51:37
Today, 5:00 PM
Fiscal Period
Q1 2026
Normalized EPS / Estimate
-/ (0.76 est.)USD
Revenue / Estimate
-/ (604.87M est.)USD
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
555.45M
568.26M
597.76M
598.66M
Cost of goods sold
19.17M
19.47M
18.57M
26.48M
Cost of revenue
19.17M
19.47M
18.57M
26.48M
Research and development expenses
212.23M
200.36M
199.16M
213.25M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
137.18M
134.86M
123.66M
123.02M
Operating expense
349.42M
335.22M
322.82M
336.27M
Total operating expenses
368.59M
354.68M
341.40M
362.75M
Operating income
186.86M
213.58M
256.36M
235.91M
Other non operating income
-245.00K
50.00K
-49.00K
46.00K
EBT including unusual items
205.69M
230.42M
252.41M
252.69M
EBT excluding unusual items
205.69M
230.42M
272.23M
253.38M
Income tax expense
46.07M
45.57M
58.84M
8.16M
Effective tax rate
22.40%
19.78%
23.31%
3.23%
Other operating expenses
-
-
-
-
Net income
159.62M
184.85M
193.58M
244.53M
Net profit margin
28.74%
32.53%
32.38%
40.85%
Earnings per share
0.62
0.75
0.78
0.94
Interest and investment income
19.08M
16.79M
15.92M
17.43M
Interest expense
-
-
-
-
Net interest expenses
19.08M
16.79M
15.92M
17.43M
Depreciation and amortization charges
-
-
-
-
EBITDA
194.20M
220.92M
263.78M
242.86M
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer